Articles

Page 4 of 6

Exploring the Impact of health-care cost sharing mechanisms in health service users for all the 27 member countries of the EU

Authors: Andreas Siakou and Costas Athanasakis

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P29

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Biosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines

Authors: Maarten Van Baelen

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P28

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Medicines optimisation in Northern Ireland - scope and results of a challenging project

Authors: Mike Scott, Frans van Andel and Rob Brenninkmeijer

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P27

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate

Authors: Elizabeth Docteur, Joshua Cohen, Brian K Bruen, Ruth Lopert, Avi Dor and Chuck Shih

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P26

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
The effective and innovative cost saving of software in managing unregistered drugs

Authors: Nur Wahida Zulkifli, Noorizan Abd Aziz, Yahaya Hassan, Mohamed Azmi Hassali and Nur Liyana Zainal Bahrin

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P25

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines

Authors: Aneta Lipińska, Maciej Pomorski, Wojciech Matusewicz and Katarzyna Jagodzińska-Kalinowska

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P24

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Pharmaceutical distribution remuneration in Europe

Authors: Sabine Vogler, Lena Lepuschütz and Peter Schneider

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P23

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Reimbursement measures in European countries – findings of a bibliometric literature review

Authors: Sabine Vogler, Nina Zimmermann, Antonio Olry de Labry and Jaime Espin

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P21

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
The prices outpatients have to pay for purchasing medicines in Armenia

Authors: Irina Kazaryan, Anahit Sevikyan and Margarit Melikyan

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P20

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Access of high technology medicines in Russia

Authors: Liudmila Bezmelnitsyna, Dmitry Meshkov and Ramil Khabriev

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P19

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Optimising prescribing in primary care: an evaluation of financial and clinical parameters

Authors: Asal Albayati, David Lu, Liam Sergeant, Nandita Singh, Keith Crump and Zaheer-Ud-Din Babar

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P18

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Reimbursement policy optimization for Angiotensin-converting enzyme (ACE) inhibitors in Bulgaria: Controlling expenditure without undermining access to treatment

Authors: Rossen M Kazakov and Penka I Petrova

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P17

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Prices of oncology medicines in European countries, Australia and New Zealand

Authors: Sabine Vogler, Agnes Vitry and Zaheer Ud-Bin-Babar

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P16

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Collaborative models for increasing efficiency of early drug assessment

Authors: Anna Nachtnebel and Claudia Wild

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O15

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Value of generic medicines: an health economics study

Authors: Martin Albrecht, Ariane Höer and Anne Zimmermann

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P15

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Cost-Containment of Non-Formulary Medicines Accessibility: Malaysian Experience

Authors: Nur Liyana Zainal Bahrin, Yahaya Hassan, Abu Bakar Abd Majeed, Nur Wahida Zulkifli and Azlan Ahmad

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P14

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
The 19th EML as a global standard: an innovative approach or just an opportunity for new and effective medicines?

Authors: Nicola Magrini, Lorenzo Moja, Bernadette Cappello, Kees De Joncheere and Gilles Forte

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O14

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Why we should have more collaboration on HTA in Europe: the example of sofosbuvir

Authors: Hedi Schelleman, Rudy Dupree, Finn B Kristensen and Wim Goettsch

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O13

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
30 years of media coverage on high drug prices in the US – a never-ending story or a time for change?

Authors: Christine Leopold, James D Chambers and Anita K Wagner

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P13

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Socioeconomic determinants of medicines use in Central Eastern Europe: the role of pharmaceutical policy in reducing inequalities

Authors: Sabine Vogler, August Österle and Susanne Mayer

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O12

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Development of pharmaceutical prices in the Republic of Macedonia in comparison to selected countries outside the national reference baskets

Authors: Kristina Hristova and Claudia Habl

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P12

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil

Authors: Yared Santa-Ana-Tellez, Veronika J Wirtz, Hubert GM Leufkens and Aukje K Mantel-Teeuwisse

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O11

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Determining the prices of the medicines in the absence of superiority over alternative medical technology

Authors: Wojciech Matusewicz, Katarzyna Jagodzińska-Kalinowska, Aneta Lipińska and Maciej Pomorski

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P11

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors

Authors: Susan Spillane, Cara Usher, Kathleen Bennett, Roisin Adams and Michael Barry

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O10

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Availability and affordability of medicines for children

Authors: Irina Kazaryan and Lusine Vardanyan

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P10

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results

Authors: Roberta Joppi, Elisa Cinconze, Luca Demattè, Renato Guseo, Claudio Jommi, Cinzia Mortarino, Daniela Pase, Chiara Poggiani, Alessandro Roggeri and Daniela Roggeri

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P9

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Approval, reimbursement and pricing of high-cost cancer medicines in Australia

Authors: Agnes Vitry

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O9

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Policy options to deal with high-cost medicines – survey with European policy-makers

Authors: Nina Zimmermann, Sabine Vogler and Hanne Bak Pedersen

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P8

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Applying Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer

Authors: Aris Angelis and Panos Kanavos

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O8

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Developing a Drug Price Reference Index in the Philippines

Authors: Manuel A Haasis, Anna M Guerrero and Marinette J Ladioray

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P7

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Using Multiple Criteria Decision Analysis (MCDA) to make coverage decisions: a methodological framework

Authors: Panos Kanavos and Aris Angelis

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O7

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Retrospective financial analysis of medicines reimbursement services in community pharmacy

Authors: Elena Chitan

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P6

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Access to subsidised medicines, cost of medicines and health outcomes: exploring general practitioners' perceptions and experiences

Authors: Zaheer-Ud-Din Babar, Abdul Ali, Christine Kim, James Mcintosh, Malaika Samuel Namdas, Erica Lourdes Rodrigues, Komal Vallabh and Anne Rew

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O6

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Scottish collaboration to integrate medicine therapy between out-patient and in-patient sectors

Authors: Kenneth R Paterson

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K6

Content type: Keynote speaker presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Pharmaceutical policies in Australia and New Zealand

Authors: Zaheer-Ud-Din Babar

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K5

Content type: Keynote speaker presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system

Authors: Dumebi O Mordi, Kwesi Eghan and Jim Rankin

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P5

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
A cost/benefit analysis of self-care initiatives in the European Union: who gains, who loses?

Authors: Anna-Theresa Renner, Julia Bobek, Herwig Ostermann, Peter Schneider and Sabine Vogler

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O5

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research?

Authors: Sabine Vogler, Nina Zimmermann and Kees De Joncheere

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):E4

Content type: Commentary

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Impact of delisting OTC medicines from reimbursement list

Authors: Petra Chytilová and Robin Šebesta

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P4

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Impact of discounts on medicine prices

Authors: Peter Schneider and Sabine Vogler

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O4

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Priority medicines for Europe and the World: setting a public-health-based medicines development agenda

Authors: Veronika J Wirtz

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K4

Content type: Keynote speaker presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Pharmaceutical pricing and reimbursement policies: perspectives for the future

Authors: Andrew L Gray

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K3

Content type: Keynote speaker presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region

Authors: Tuan A Nguyen, Sun Qiang, Haipeng Wang, Krishna Undela and Agnes Vitry

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P3

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure

Authors: Anna Lukačišinová and Helena Skácelová

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O3

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Policies beyond the crisis: lesson learned

Authors: Sabine Vogler, Nina Zimmermann, Veronika J Wirtz and Zaheer-Ud-Din Babar

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):E2

Content type: Editorial

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Impact of Generic Price Linkage System and Reference Price System on prices of pharmaceuticals – comparison of Austria and Finland

Authors: Jaana E Martikainen, Timo Maljanen, Hanna Koskinen and Sabine Vogler

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P2

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs

Authors: Elizabeth Docteur and Ruth Lopert

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O2

Content type: Oral presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Challenges and opportunities for pharmaceutical pricing and reimbursement policies

Authors: Sabine Vogler, Nina Zimmermann, Alessandra Ferrario, Veronika J Wirtz and Zaheer-Ud-Din Babar

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):E1

Content type: Editorial

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Affordable innovation: future directions in pharmaceutical policy

Authors: Suzanne R Hill

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K1

Content type: Keynote speaker presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF
Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin

Authors: Jessica Fraeyman, Hans De Loof, Guido Van Hal, Guido De Meyer, Roy Remmen and Philippe Beutels

Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P1

Content type: Poster presentation

Published on: 5 October 2015

This article is part of a Supplement: Volume 8 Supplement 1
- View Full Text
- View PDF

Articles

Follow

Annual Journal Metrics

Journal of Pharmaceutical Policy and Practice

Contact us